One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherpay

Chinese Journal of Cancer

Volumn 29, Issue 12, 2010, Pages 1023-1028

  Xia, Liang Ping ^a   Wu, Pei Hong ^a   Xia, Jian Chuan ^a   Zhang, Bei ^a   Guan, Zhong Zhen ^a   Wan, De Sen ^a   Guo, Gui Fang ^a   Zeng, Yi Xin ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Combination; Metastatic colorectal cancer; Progression free survival; Targeted agents

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; GEFITINIB; LONICERA JAPONICA EXTRACT; OXALIPLATIN;

ADVANCED CANCER; ARTICLE; BIOLOGICAL THERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CHINESE MEDICINE; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE INDUCED KILLER CELL; DERMATITIS; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FACE RASH; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PARONYCHIA; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RASH;

EID: 79955842204     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.010.10051     Document Type: Article

References (30)

1. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer [J]. N Engl J Med, 2009, 360(14): 1408-1417.
2. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer [J]. J Clin Oncol, 2009, 27(5): 663-671.
3. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26(14): 2311-2319.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med, 2004, 351(4): 337-345.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J]. N Engl J Med, 2004, 350: 2335-2342.
6. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 [J]. J Clin Oncol, 2007, 25(12): 1539-1544.
7. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301 [J]. J Clin Oncol, 2006, 24(21): 3354-3360.
8. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer [J]. N Engl J Med, 2009, 360(6): 563-572.
9. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer [J]. J Clin Oncol, 2009, 27(5): 672-680.
10. Guarino MJ, Schneider CJ, Hosford MA, et al. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies [J]. Oncologist, 2009, 14(2): 119-124.
11. Wang Y, Xu JM, Xu QZ, et al. Combination with SN-38 on human colon cancer LoVo cells [J]. Chin J Oncol, 2009, 31(10): 746-851. [in Chinese]
12. Xu JM. Several issues faced by molecular targeted therapy in colorectal cancer [J]. Chin J Oncol, 2009, 31 (5): 321-323. [in Chinese]
13. Mountzios G, Soria JC. Advanced non-small-cell lung cancer: "triplets" better than "doublets"? [J]. Nat Clin Pract Oncol, 2006, 3(9): 476-477.
14. Zhang YF, Chen ZW, Lu S. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer [J]. J Chin Med, 2009, 122 (20): 2472-2476.
15. Weihrauch MR, Stippel D, Fries JW, et al. Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment [J]. Onkologie, 2008, 31 (8-9): 464-467.
16. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study [J]. J Clin Oncol, 2007, 25(29): 4557-4561.
17. Halama N, Herrmann C, Jaeger D, et al. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer [J]. Anticancer Res, 2008, 28(6B): 4111-4115.
18. Moosmann N, Laessig D, Michaely HJ, et al. Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [J]. Onkologie, 2007, 30(10): 509-512.
19. Arteaga CL, O'Neill A, Moulder SL, et al. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer [J]. Clin Cancer Res, 2008, 14(19): 6277-6283.
20. Lin CC, Calvo E, Papadopoulos KP, et al. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors [J]. Cancer Chemother Pharmacol, 2009, 63(6): 1065-1071.
21. Larbouret C, Robert B, Bascoul-Mollevi C, et al. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts [J]. Ann Oncol, 2010, 21(1): 98-103.
22. Kondo N, Ishiguro Y, Kimura M, et al. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab [J]. Oncol Rep, 2008, 20(2): 373-378.
23. Prichard CN, Kim S, Yazici YD, et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma [J]. Laryngoscope, 2007, 117(4): 674-679.
24. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med, 2008, 359 (4): 378-390.
25. Piessevaux H, Buyse M, De Roock W, et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial) [J]. Ann Oncol, 2009, 20(8): 1375-1382.
26. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy [J]. N Engl J Med, 2006, 354(5): 496-507.
27. Chitale D, Gong Y, Taylor BS, et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors [J]. Oncogene, 2009, 28(31): 2773-2783.
28. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma [J]. Nature, 2008, 455(7216): 1069-1075.
29. Pessino A, Artale S, Sciallero S, et al. First-line single-agent cetuximab in patients with advanced colorectal cancer [J]. Ann Oncol, 2008, 19(4): 711-716.
30. Mack PC, Holland WS, Redman M, et al. KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536 [J]. ASCO Meeting Abstracts, May 20 2009: 8022.